KAKUHIRO YAMAGUCHI

Last Updated :2023/11/01

Affiliations, Positions
Hiroshima University Hospital, Assistant Professor
E-mail
yamakakuhiroshima-u.ac.jp

Basic Information

Academic Degrees

  • Hiroshima University

Affiliated Academic Societies

  • The Japanese Respiratory Society
  • Japanese Society of Medical Oncology
  • The Japan Lung Cancer Society
  • The Japan Society for Respiratoty Endoscopy
  • The Japanese Society of Internal Medicine

Educational Activity

Course in Charge

  1. 2023, Undergraduate Education, Year, Clinical diagnosis and treatment I
  2. 2023, Undergraduate Education, Intensive, Practice of Medicine I
  3. 2023, Undergraduate Education, Intensive, Practice of Medicine II

Research Activities

Academic Papers

  1. Serum and bronchoalveolar lavage fluid levels of soluble B7H3 in patients with interstitial lung diseases, RESPIRATORY MEDICINE, 212, 202306
  2. Predictive value of serum high-mobility group box 1 levels for checkpoint inhibitor pneumonitis, RESPIROLOGY, 28(4), 380-388, 202304
  3. Preserved ratio impaired spirometry with or without restrictive spirometric abnormality, SCIENTIFIC REPORTS, 13(1), 20230220
  4. A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy, LUNG CANCER, 177, 44-50, 202303
  5. Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal Transition, CANCERS, 15(4), 202302
  6. ★, Association of the RAGE/RAGE-ligand axis with interstitial lung disease and its acute exacerbation, RESPIRATORY INVESTIGATION, 60(4), 531-542, 202207
  7. Association Between Patient Preference for Inhaler Medications and Asthma Outcomes, JOURNAL OF ASTHMA AND ALLERGY, 15, 1539-1547, 2022
  8. Dupilumab as an adjunct treatment for a patient with steroid-dependent immunoglobulin G4-related disease complicated by asthma: a case report, JOURNAL OF ASTHMA, 59(12), 2395-2401, 20221110
  9. Predictive role of circulatory levels of high-mobility group box 1 for radiation pneumonitis in patients with non-small cell lung cancer treated with definitive thoracic radiotherapy, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 27(11), 1698-1705, 202211
  10. Pneumonia and Meningoencephalitis Due to Varicella-zoster Virus Reinfection and Epstein-Barr Virus Reactivation in a Patient with Rheumatoid Arthritis, INTERNAL MEDICINE, 61(19), 2961-2965, 2022
  11. Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer, BMC PULMONARY MEDICINE, 22(1), 20220630
  12. Role of Soluble Receptor for Advanced Glycation End Products in Postoperative Fibrotic Lung Injury, ANNALS OF THORACIC SURGERY, 113(5), 1617-1623, 202205
  13. Vocal cord dysfunction detected by a three-dimensional image of dynamic change in respiratory resistance in a patient with difficult-to-treat asthma: a case report, JOURNAL OF ASTHMA, 59(6), 1157-1161, 20220603
  14. Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1, THORACIC CANCER, 13(11), 1611-1618, 202206
  15. Primary Pulmonary Mucosa-associated Lymphoid Tissue Lymphoma with the High Expression of IgG4, INTERNAL MEDICINE, 61(7), 1043-1048, 2022
  16. Tolerability and efficacy of IMpower133 regimen modified for dialysis patients with extensive-stage small cell lung cancer: Two case reports, THORACIC CANCER, 12(21), 2956-2960, 202111
  17. Pulmonary Alveolar Proteinosis with Severe Respiratory Failure Improved by Segmental Lung Lavage with Fiberoptic Bronchoscopy under General Anesthesia, INTERNAL MEDICINE, 61(3), 389-393, 2022
  18. Pneumatosis Intestinalis following Radiation Esophagitis during Chemoradiotherapy for Lung Cancer: A Case Report, CASE REPORTS IN ONCOLOGY, 14(3), 1454-1459, 2021
  19. Accelerated decline in lung function in adults with a history of remitted childhood asthma, EUROPEAN RESPIRATORY JOURNAL, 59(1), 20220101
  20. First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations, THORACIC CANCER, 13(5), 771-774, 202203
  21. ★, AGER gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosis., Respirology., 22(5), 965-971, 2017
  22. Obstinate hyponatremia and hypoglycemia caused by pituitary metastasis of lung cancer, 2(3), 279-283, 2013
  23. A Case of Asian Variant Intravascular Large B-cell Lymphoma Diagnosed Based on a Thoracoscopic Lung Biopsy That Exhibited Remission and Exacerbation on Computed Tomography, 53(2), 99-103, 2013
  24. Thymic Carcinoma Treated with Carboplatin and Nab-paclitaxel as Second-line Chemotherapy, 74(8), 900-908, 2015
  25. ★, AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma, ONCOTARGET, 8(55), 94382-94392, 20171107
  26. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma, LUNG CANCER, 119, 21-24, 201805
  27. Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets, BMC Med Genet, 18(1), 88, 2017
  28. Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study, IN VIVO, 32(5), 1155-1160, 2018
  29. Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility study, MOLECULAR AND CLINICAL ONCOLOGY, 9(5), 539-544, 201811
  30. Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody A retrospective cohort study, MEDICINE, 97(49), 201812
  31. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1, CANCER LETTERS, 442, 31-39, 2019
  32. High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery, MEDICINE, 98(5), 201902
  33. Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma A case report, MEDICINE, 98(12), 201903
  34. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts, JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 23(4), 2984-2994, 201904
  35. Performance Status Is a Risk Factor for Depression before the Diagnosis of Lung Cancer Patients, INTERNAL MEDICINE, 58(7), 915-920, 2019
  36. Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress, FREE RADICAL BIOLOGY AND MEDICINE, 136, 52-59, 20190520
  37. Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia, RESPIRATORY MEDICINE, 152, 44-50, 201906
  38. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer, RESPIRATORY INVESTIGATION, 57(5), 451-459, 201909
  39. C-C Motif Chemokine Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity Pneumonitis, RESPIRATION, 98(3), 212-220, 201909
  40. Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer, ANTICANCER RESEARCH, 39(10), 5725-5731, 201910
  41. Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis, INTERNAL MEDICINE, 58(21), 3129-3132, 2019
  42. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 25(1), 74-81, 20200101
  43. Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer, JOURNAL OF THORACIC DISEASE, 12(3), 1079-1084, 20200301
  44. ★, Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis, RESPIROLOGY, 25(3), 275-280, 20200301
  45. ★, Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis, RESPIRATORY RESEARCH, 21(1), 20200611
  46. A Case of Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis., Intern Med., 58, 3129-3132, 2019
  47. ★, Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease, RESPIRATORY MEDICINE, 172, 20200828
  48. Extent of pulmonary fibrosis on high-resolution computed tomography is a prognostic factor in patients with pleuroparenchymal fibroelastosis, RESPIRATORY INVESTIGATION, 58(6), 465-472, 20200803
  49. Coexisting TIF1 gamma-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1 gamma Antibody-positive Dermatomyositis, INTERNAL MEDICINE, 59(20), 2553-2558, 20201015
  50. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers, JAMA NETWORK OPEN, 3(11), 20201112
  51. Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancer, CANCER SCIENCE, 112(1), 369-379, 20201112
  52. Correlations of forced oscillometric bronchodilator response with airway inflammation and disease duration in asthma, CLINICAL RESPIRATORY JOURNAL, 15(1), 48-55, 20210914
  53. Two Cases of Cranial Nerve Metastasis Treated with Radiotherapy and Chemotherapy in Patients with Lung Adenocarcinoma, CASE REPORTS IN ONCOLOGY, 13(3), 1495-1500, 20201217
  54. Alectinib-induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma, INTERNAL MEDICINE, 60(4), 611-615, 20200930
  55. Concomitant emphysema might increase the false-negative rate of urinary antigen tests in patients with pneumococcal pneumonia: results from a retrospective study, EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 40(4), 871-877, 20201104
  56. Autoantibody Positivity Is a Risk Factor for Chemotherapy-induced Exacerbation of Interstitial Pneumonia in Lung Cancer, ANTICANCER RESEARCH, 41(3), 1497-1506, 20210301
  57. Pulmonary lymphangitic carcinomatosis from recurrent gastric cancer 19 years after primary resection: a case report, CLINICAL JOURNAL OF GASTROENTEROLOGY, 14(2), 484-488, 20210401
  58. Pulmonary arteriovenous malformation exhibiting recanalization >10 years after coil embolization Two case reports, MEDICINE, 99(2), 20200101
  59. Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone, ANTICANCER RESEARCH, 41(5), 2661-2667, 20210501
  60. ★, Predictive role of circulatory HMGB1 in postoperative acute exacerbation of interstitial lung disease in lung cancer patients, SCIENTIFIC REPORTS, 11(1), 20210512
  61. Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study, PULMONARY PHARMACOLOGY & THERAPEUTICS, 67, 20210208
  62. D-dimer can be a diagnostic marker for cisplatin-related aortic thrombosis A case report, MEDICINE, 100(7), 20210219
  63. A machine-learning based approach to quantify fine crackles in the diagnosis of interstitial pneumonia A proof-of-concept study, MEDICINE, 100(7), 20210219
  64. IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis, PLOS ONE, 16(6), 20210604
  65. Quantitative parameters of lymphocyte nuclear morphology in bronchoalveolar lavage fluid as novel biomarkers for sarcoidosis, ORPHANET JOURNAL OF RARE DISEASES, 16(1), 20210703
  66. A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based (WJOG12819L), CLINICAL LUNG CANCER, 22(4), 376-380, 20210125
  67. Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity, STEM CELL RESEARCH & THERAPY, 12(1), 20210823
  68. Human bone marrow-derived mesenchymal stromal cells cultured in serum-free media demonstrate enhanced antifibrotic abilities via prolonged survival and robust regulatory T cell induction in murine bleomycin-induced pulmonary fibrosis, STEM CELL RESEARCH & THERAPY, 12(1), 20210916
  69. Analysis of microRNA Expression in Liquid-Based Cytology Samples May Be Useful for Primary Lung Cancer Diagnosis, AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 156(4), 644-652, 202110
  70. Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 88(5), 857-865, 202111
  71. Rapid changes of nailfold capillary abnormalities during treatment for a patient with dermatomyositis complicated by lung cancer: a case report, MODERN RHEUMATOLOGY CASE REPORTS, 5(1), 95-100, 20210102

Invited Lecture, Oral Presentation, Poster Presentation

  1. A study of lung cancer cases participated in cancer genome medicine at our hospital, Sumii M, Namba M, Tokumo K, Yamauchi M, Nakahara H, Urabe Y, Nelson HC, Itamura R, Motonaga M, Sakamoto S, Yamaguchi K, Masuda T, Fujitaka K, Okamoto W, Arihiro K, Hiyama E, Hattori N, Hinoi T, Sugiyama K, JSMO 2023, 2023/03/16, Without Invitation, English
  2. The difference in predictive value for checkpoint inhibitor pneumonitis between serum and plasma levels of HMGB1, Yamaguchi K, Tanahashi H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N, JSMO 2023, 2023/03/16, Without Invitation, English
  3. Phase 2 study of first-line pembrolizumab in elderly patients with non-small cell lung cancer expressing high PD-L1., Hamai K, Masuda T, Fujitaka K, Suzuki T, Matsumoto N, Matsumura M, Isoyama S, Ueno S, Mito M, Yamaguchi K, Sakamoto S, Kawano R, Masuda K, Nishino R, Ishikawa N, Yamasaki M, Hattori N, 2022 ASCO Annual Meeting, 2022/06/03, Without Invitation, English
  4. The associations between patients' preference for inhaled medications and asthma control, Nakanishi Y, Iwamoto H, Miyamoto S, Nakao S, Higaki N, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Matsumoto N, Nakashima T, Onari Y, Fujitaka K, Haruta Y, Hamada H, Hozawa S, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11/20, Without Invitation, English
  5. A case of pulmonary alveolar proteinosis with severe respiratory failure improved by segmental lung lavage with fiberoptic bronchoscopy under general anesthesia, Matsumoto Y, Masuda T, Takahashi H, Hashimoto K*, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Ohshimo S, Fujitaka K, Yamasaki M, Hamada M, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, Without Invitation, English
  6. Clinical characteristics of Preserved Ratio Impaired Spirometry in Japan, Miura S, Iwamoto H, Omori K, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Yokoyama A, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11/20, Without Invitation, English
  7. Current status and future challenges of lung cancer genome medicine at our hospital, Namba M, Tokumo K, Yamauchi M, Nakahara H, Urabe Y, Nelson HC, Teratani Y*, Kobayashi R, Itamura R, Motonaga M, Sakamoto S, Yamaguchi K, Masuda T, Fujitaka K, Okamoto W, Arihiro K, Hiyama E, Hattori N, Hinoi T, Sugiyama K, The 25th Congress of the Asian Pacific Society of Respirology, Without Invitation, English
  8. Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity, Takahashi H, Nakashima T, Masuda T, Namba M, Sakamoto S, Yamaguchi K, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11/20, Without Invitation, English
  9. The role of circulatory high-mobility group box 1 for predicting checkpoint inhibitor pneumonitis caused by anti-PD-1/PD-L1 antibody monotherapy, Yamaguchi K, Tanahashi H, Kurose K, Nakao S, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Oga T, Oka M, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11/20, Without Invitation, English
  10. Autoantibody positivity is a risk factor for chemotherapy-induced exacerbation of interstitial pneumonia in lung cancer, Ito N, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11/20, Without Invitation, English
  11. Mesenchymal stem cells cultured in serum-free medium suppress murine bleomycin-induced pulmonary fibrosis by enhancing regulatory T cell induction, Takao S, Nakashima T, Masuda T, Namba M, Sakamoto S, Yamaguchi K, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Nakashima A, Hattori N, The 25th Congress of the Asian Pacific Society of Respirology, 2021/11/20, Without Invitation, English
  12. Association between glucose intolerance and chemotherapy-induced lung injury in lung cancer with interstitial pneumonia, Otani T, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N., 2021/02/18, Without Invitation, English
  13. Association of Pre-Existing Interstitial Lung Abnormalities with Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients with Non-Lung Cancers, Shimoji K, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, MiyamotoS, Iwamoto H, Fujitaka K, Hamada H, Takeno S*, Hide M*, Teishima J*, Ohdan H*, Hattori N., 2021/02/18, Without Invitation, English
  14. Decline of lung function in adults with a history of childhood asthma, Miura S, Iwamoto H, Omori K, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Yokoyama A*, Hattori N., JSA/WAO Joint Congress 2020, 2020/09/17, Without Invitation, English
  15. Real-world study of prescription pattern of inhaled corticosteroids in adult asthma, Nakanishi Y, Iwamoto H, Nakao S, Higaki N, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Matsumoto N, Nakashima T, Miyamoto S, Onari Y, Fujitaka K, Haruta Y, Hamada H, Hozawa S, Hattori N., JSA/WAO Joint Congress 2020, 2020/09/17, Without Invitation, English
  16. Correlations of forced oscillometric bronchodilator response with airway inflammation and disease duration in asthma, Higaki N, Iwamoto H, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Hattori N., JSA/WAO Joint Congress 2020, 2020/09/17, Without Invitation, English
  17. Pivotal role of the HMGB1/sRAGE axis in drug-induced lung injury in advanced lung cancer with pre-existing interstitial lung disease, Nakao S, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N., 30th International Congress of the European Respiratory Society, 2020/09/05, Without Invitation, English
  18. IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis, Nakanishi Y, Horimasu Y, Yamaguchi K, Sakamoto S, Masuda T, Nakashima T, Miyamoto S, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori, N., 30th International Congress of the European Respiratory Society, 2020/09/05, Without Invitation, English
  19. Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis, Yamaguchi K, Iwamoto H, Mazur W*, Miura S, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N., 30th International Congress of the European Respiratory Society, 2020/09/05, Without Invitation, English
  20. Increased fraction of small round lymphocyte in BALF is a diagnostic indicator for sarcoidosis, Horimasu Y, Yamaguchi K, Sakamoto S, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N., 30th International Congress of the European Respiratory Society, 2020/09/05, Without Invitation, English
  21. Difference between pathogenic and inhibitory bacterial florae is associated with acute exacerbation of idiopathic pulmonary fibrosis, Ohshimo S, Nishi H*, Yamaguchi K, Horimasu Y, Masuda T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Kawaguchi H*, Bonella F*, Guzman J*, Costabel U*, Hattori N, Shime N*., 30th International Congress of the European Respiratory Society, 2020/09/05, Without Invitation, Japanese
  22. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-NSCLC cancers., Shimoji K, Masuda T, Nakanishi Y, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N., 2020 ASCO Annual Meeting, 2020/05/29, Without Invitation, English
  23. Clinical significance of BIM deletion polymorphism on chemoradiotherapy in patients with non-small cell lung cancer, Wakabayashi Y, Masuda T, Nakashima T, Fujitaka K, Yamaguchi K, Sakamoto S, Nishimura Y, Horimasu Y, Miyamoto S, Senoo T, IwamotoH, Ohshimo S, Hamada H, Hattori N, 2020 ASCO Annual Meeting, 2020/05/29, Without Invitation, English
  24. EGFR gene mutation is not a significant risk factor in patients with EGFR mutated non-small cell lung cancer who receive best supportive care alone, Masuda T, Wakabayashi Y, Shimoji K, Yamaguchi K, Sakamoto S, Nishimura Y, Horimasu Y, Nakashima T, Miyamoto S, Senoo T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N., 2020 ASCO Annual Meeting, 2020/05/29, Without Invitation, English
  25. Serum high mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis, Yamaguchi K,, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N., European Respiratory Society International Congress 2019, 2019/09/28, Without Invitation, English, Madrid
  26. Decreased circulatory receptor for advanced glycation end-products is associated with poorer survival in patients with idiopathic pulmonary fibrosis., Kakuhiro Yamaguchi, Hiroshi Iwamoto, Yasushi Horimasu, Takeshi Masuda, Taku Nakashima, Shintaro Miyamoto, Shinichiro Ohshimo, Kazunori Fujitaka, Noboru Hattori, Witold Mazur, Nobuoki Kohno., 2016, Without Invitation, English
  27. Extent of the Honeycombing Area and the Presence of Traction Bronchiectasis are Risk Factors for Poorer Prognosis in Patients with Pleuroparenchymal Fibroelastosis., Namba M,, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N, American Thoracic Society 2018 International Conference, 2018/05/18, Without Invitation, English
  28. PAI-1 Influences the Effectiveness of Chemotherapy Through Its Association with Apoptosis in Cancer-Associated Myofibroblasts, T. Masuda., T. Nakashima , M. Namba , K. Yamaguchi , S. Sakamoto , Y. Horimasu , S. Miyamoto , H. Iwamoto , K. Fujitaka , H. Hamada , N. Hatttori, American Thoracic Society 2018, 2018/05/18, Without Invitation, English

Awards

  1. 2021/11/21, JRS Young Scientist Award, APSR, The role of circulatory high-mobility group box 1 for predicting checkpoint inhibitor pneumonitis caused by anti-PD-1/PD-L1 antibody monotherapy

External Funds

Acceptance Results of Competitive Funds

  1. 2020, 2021
  2. 2021, 2021
  3. 2018, 2020